{"nctId":"NCT00483652","briefTitle":"Study of Fampridine-SR Tablets in Multiple Sclerosis Patients","startDateStruct":{"date":"2007-05"},"conditions":["Multiple Sclerosis"],"count":240,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Fampridine-SR","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Fampridine-SR"]}],"interventions":[{"name":"Fampridine-SR","otherNames":["4-aminopyridine"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient with clinically defined multiple sclerosis\n* All patients must be able to complete two trials of a timed 25 foot walk\n\nExclusion Criteria:\n\n* Female patients who are either pregnant or breastfeeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Responders Based Upon the Timed 25-Foot Walk [T25FW]","description":"A responder is a patient who showed faster walking speed for at least 3 visits out of a possible 4 during the double-blind period than the maximum value achieved in the 5 non-double-blind no-treatment visits (4 before the double-blind period and one after)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Lower Extremity Manual Muscle Test [LEMMT]","description":"Evaluator rated strength in hip flexors, knee flexors, knee extensors, and ankle dorsiflexors on the following scale: best value = 5.0 (normal muscle strength), worst value = 0.0 (absence of any voluntary contraction). A positive shift in LEMMT score shows improvement in strength. Change in LEMMT scores for the secondary efficacy measure was found by averaging the LEMMT scores on days 14, 28, 42, and 56 (double-blind treatment period) and subtracting the baseline LEMMT score.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.219"},{"groupId":"OG001","value":"0.04","spread":"0.253"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":120},"commonTop":["Fall","Urinary tract infection","Asthenia","Upper respiratory tract infection","Insomnia"]}}}